FGFR-TKI resistance in cancer: current status and perspectives
S Yue, Y Li, X Chen, J Wang, M Li, Y Chen… - Journal of hematology & …, 2021 - Springer
Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation,
differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase …
differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase …
Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors
Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …
Deep generative neural network for accurate drug response imputation
Drug response differs substantially in cancer patients due to inter-and intra-tumor
heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has …
heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has …
The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention
ABSTRACT Fibroblast Growth Factor (FGF) ligands and their receptors are crucial factors
driving chemoresistance in several malignancies, challenging the efficacy of currently …
driving chemoresistance in several malignancies, challenging the efficacy of currently …
[HTML][HTML] Targeting KRAS-mutant non–small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations
TF Burns, H Borghaei, SS Ramalingam… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Lung cancer represents 11.6% of all cancers globally, with more than 2 million new cases
worldwide in 2018. 1 Across all disease stages, non–small-cell lung cancer (NSCLC) has an …
worldwide in 2018. 1 Across all disease stages, non–small-cell lung cancer (NSCLC) has an …
Fructose-1, 6-bisphosphatase inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1–MAPK interaction
Dysregulation of the MAPK pathway correlates with progression of pancreatic ductal
adenocarcinoma (PDAC) progression. IQ motif containing GTPase-activating protein 1 …
adenocarcinoma (PDAC) progression. IQ motif containing GTPase-activating protein 1 …
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells
N Sugito, K Heishima, Y Akao - Molecular Therapy-Nucleic Acids, 2022 - cell.com
Kirsten rat sarcoma virus (KRAS) mutations are frequently detected in many cancers and are
major driver genes. Therefore, KRAS inhibitors have been the subject of extensive research …
major driver genes. Therefore, KRAS inhibitors have been the subject of extensive research …
KRas G12C inhibitors
JF Blake, LE Burgess, MJ Chicarelli… - US Patent …, 2018 - Google Patents
2018-05-31 Assigned to Mirati Therapeutics, Inc. reassignment Mirati Therapeutics, Inc.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
[HTML][HTML] Real-time sensing of MAPK signaling in medulloblastoma cells reveals cellular evasion mechanism counteracting dasatinib blockade of ERK activation during …
MT Schönholzer, J Migliavacca, E Alvarez, KS Kumar… - Neoplasia, 2020 - Elsevier
Aberrantly activated kinase signaling pathways drive invasion and dissemination in
medulloblastoma (MB). A majority of tumor-promoting kinase signaling pathways feed into …
medulloblastoma (MB). A majority of tumor-promoting kinase signaling pathways feed into …
Par-4 activation restrains EMT-induced chemoresistance in PDAC by attenuating MDM-2
Background We recently reported prostate apoptosis response 4 (Par-4), a potential tumor
suppressor protein restrains epithelial-mesenchymal transition (EMT) properties and …
suppressor protein restrains epithelial-mesenchymal transition (EMT) properties and …